UKRI and BBSRC award £170m to 3 UK universities for biotech and biology PhD studentships
pharmafile | October 28, 2019 | News story | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | UK, pharma, research
The Biotechnology and Biological Sciences Research Council (BBSRC) and UK Research and Innovation (UKRI) have awarded a funding injection of £170 million to three key UK universities following a successful bid.
The bid was made in the third round of a programme between UKRI and BBSRC known as the Newcastle, Liverpool and Durham (NLD) Doctoral Training Partnership (DTP), which aims to train talent in areas “relevant to the remit and strategic research priority areas of BBSRC” across each of the cities’ universities.
The sum will fund the studentships of 1,700 PhD researchers in biotechnology and biological science over a five-year period, including four industrial CASE (iCASE) studentship awards per year, starting in October 2020. The funding provided will also be matched by the recipient universities, allowing the support of 28 studentships annually.
“Our Doctoral Training Partnerships have already supported the training of hundreds of early career scientists working at the cutting edge of biology and biotechnology,” commented Professor Melanie Welham, BBSRC’s Executive Chair. “By continuing to fund, through this significant £170 million investment, vital training of the next generation of researchers we will help ensure that the UK consolidates its position as world-leader in this crucial sector.”
Professor Andy Jones, NLD DTP Director at the University of Liverpool, also remarked: “We are delighted to secure this new award, which recognises the strength of our partnership and the quality of research across key thematic areas of the BBSRC. There is a particular emphasis on agri-food research, and training will include exploiting new ways of working and ‘big data’.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
